Compliance Law360 provides cutting-edge news and analysis of interest to corporate compliance officers and the lawyers and consultants who advise them. From real-time information and data on regulation and enforcement to incisive features on the increasing demands facing chief compliance officers in today’s world, the wire aims to be a one-stop shop for CCOs looking to stay abreast with a complex world.

Sign up for a 7-day FREE trial today!

Latest News in Compliance

• March 25, 2026

  Oak View Exec Tells Jury Of Deal To Hype Ticketmaster

  The CEO of Oak View Group told a Manhattan federal jury Wednesday that his company didn't inform other venue owners that it was being paid to "advocate" for them to use Ticketmaster as a vendor for ticketing services, but said he still would recommend the Live Nation subsidiary anyway since it's the best in the business.

• March 25, 2026

  Lawmakers Probe SEC Rulemaking Role In Tokenization

  House lawmakers on Wednesday voiced support for bringing blockchain technology to Wall Street securities trading if it improves settlement times and market transparency, but Democrats worried whether certain regulatory experiments could lead to less oversight for crypto securities than their traditional counterparts. 

• March 25, 2026

  UBS Must Face Class Action Over Low-Yield Sweep Accounts

  A New York federal judge on Wednesday trimmed a proposed class action alleging USB Financial Services Inc. put customers' money in low-yielding "cash sweep" accounts in breach of their contract, tossing a single duplicative unjust enrichment claim but allowing the contract claims to proceed.

• March 25, 2026

  Nexstar Says No Harm On The Horizon From $6.2B Tegna Deal

  Nexstar and Tegna have come out swinging against a "last-minute, unfounded" attempt by eight states to block the companies from continuing to co-mingle their businesses following their $6.2 billion television station merger after receiving the go-ahead from the Federal Communications Commission.

• March 25, 2026

  AbbVie, Novartis Sue Wash. Over New 340B Drug-Pricing Law

  Pharmaceutical giants Novartis and AbbVie say a new Washington state law illegally expands drugmakers' obligations to provide deeply discounted medications under the federal government's 340B Drug Pricing Program, according to a pair of legal challenges launched in federal court on Wednesday.

See more Compliance news